Saint Paul, Minnesota, USA, 19 January 2021 – Squarex Pharma (SQX), a St. Paul, Minnesota, USA-based company, announced updated results from its Phase 2 clinical study on humans with its novel asset SQX770 for prevention of cold sores also known as herpes labialis or oral herpes, an illness caused by herpes simplex virus, usually type 1 (HSV-1).
SQX770 is a unique, first in class topical immunomodulator. SQX770 is the only product shown to reduce the number of cold sore events or flareups as well as their severity.
April 2, 2021
Developing Options for Not Just Treating, But Preventing,
Outbreaks of Herpes Labialis (Cold Sores or Oral Herpes)
April 20, 2021
Squarex, LLC, Announces the Hiring
of Joseph Cunningham as CFO
Copyright © 2023 Squarex - All Rights Reserved.
Powered by GoDaddy Website Builder
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.